Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.
Market Cap & Net Worth: Hwail Pharmaceutical Co.Ltd (061250)
Hwail Pharmaceutical Co.Ltd (KQ:061250) has a market capitalization of $52.59 Million (₩77.00 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #27219 globally and #1799 in its home market, demonstrating a -6.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hwail Pharmaceutical Co.Ltd's stock price ₩918.00 by its total outstanding shares 83882778 (83.88 Million).
Hwail Pharmaceutical Co.Ltd Market Cap History: 2015 to 2026
Hwail Pharmaceutical Co.Ltd's market capitalization history from 2015 to 2026. Data shows change from $112.36 Million to $52.59 Million (-6.38% CAGR).
Index Memberships
Hwail Pharmaceutical Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.61 Billion | 0.01% | #978 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.61 Billion | 0.01% | #978 of 1384 |
Weight: Hwail Pharmaceutical Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hwail Pharmaceutical Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hwail Pharmaceutical Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Hwail Pharmaceutical Co.Ltd's market cap is 0.00 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.01x
Hwail Pharmaceutical Co.Ltd's market cap is 0.01 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $112.36 Million | $106.13 Billion | $5.45 Billion | 0.00x | 0.02x |
| 2016 | $143.49 Million | $111.52 Billion | $6.38 Billion | 0.00x | 0.02x |
| 2017 | $123.24 Million | $102.46 Billion | $2.67 Billion | 0.00x | 0.05x |
| 2018 | $120.45 Million | $102.07 Billion | $5.08 Billion | 0.00x | 0.02x |
| 2019 | $123.55 Million | $108.74 Billion | $3.19 Billion | 0.00x | 0.04x |
| 2020 | $240.61 Million | $123.61 Billion | $2.81 Billion | 0.00x | 0.09x |
| 2021 | $150.10 Million | $106.99 Billion | $2.84 Billion | 0.00x | 0.05x |
| 2022 | $159.26 Million | $132.05 Billion | -$6.33 Billion | 0.00x | N/A |
| 2023 | $126.32 Million | $122.54 Billion | $3.86 Billion | 0.00x | 0.03x |
| 2024 | $73.44 Million | $119.76 Billion | $6.48 Billion | 0.00x | 0.01x |
Competitor Companies of 061250 by Market Capitalization
Companies near Hwail Pharmaceutical Co.Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Hwail Pharmaceutical Co.Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hwail Pharmaceutical Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hwail Pharmaceutical Co.Ltd's market cap moved from $112.36 Million to $ 52.59 Million, with a yearly change of -6.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩52.59 Million | -19.69% |
| 2025 | ₩65.48 Million | -10.84% |
| 2024 | ₩73.44 Million | -41.86% |
| 2023 | ₩126.32 Million | -20.68% |
| 2022 | ₩159.26 Million | +6.11% |
| 2021 | ₩150.10 Million | -37.62% |
| 2020 | ₩240.61 Million | +94.75% |
| 2019 | ₩123.55 Million | +2.58% |
| 2018 | ₩120.45 Million | -2.27% |
| 2017 | ₩123.24 Million | -14.11% |
| 2016 | ₩143.49 Million | +27.71% |
| 2015 | ₩112.36 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Hwail Pharmaceutical Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.59 Million USD |
| MoneyControl | $52.59 Million USD |
| MarketWatch | $52.59 Million USD |
| marketcap.company | $52.59 Million USD |
| Reuters | $52.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.